- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06674863
Op maat gemaakt overlevingszorgplan om het begrip en de toegang tot overlevingszorg bij zwarte of Afro-Amerikaanse patiënten met gelokaliseerde of oligometastatische prostaatkanker te verbeteren
Gezondheidsgeletterdheid aanpakken met een op maat gemaakt overlevingszorgplan om de toegang te verbeteren voor achtergestelde Afro-Amerikaanse prostaatkankerpatiënten
This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. Compare outcomes after patients receive usual care from their providers with a standard SCP and after patients receive tailoring of the SCP with the low literacy educational supplement.
II. To quantify the potential benefit of tailoring the care plan and the educational supplement.
III. Compare providers' assessment of patients':
IIIa. Health literacy; IIIb. Comprehension of survivorship care recommendations; IIIc. Understanding of long term and late effects from treatment; IIId. To measures obtained from patients.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (INTERVENTION): Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.
GROUP II (CONTROL): Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Kerry L. Kilbridge, MD, MSc
- Telefoonnummer: 617-632-2429
- E-mail: Kerry_Kilbridge@DFCI.HARVARD.EDU
Studie Locaties
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Werving
- Emory University Hospital/Winship Cancer Institute
-
Contact:
- Sierra Williams
- Telefoonnummer: 404-778-4898
- E-mail: sierra.williams@emory.edu
-
Hoofdonderzoeker:
- Viraj Master, MD, PhD, FACS
-
Atlanta, Georgia, Verenigde Staten, 30303
- Werving
- Grady Memorial Hospital
-
Contact:
- Sierra Williams
- Telefoonnummer: 404-778-4729
- E-mail: sierra.williams@emory.edu
-
Hoofdonderzoeker:
- Viraj Master, MD, PhD, FACS
-
Atlanta, Georgia, Verenigde Staten, 30329
- Werving
- Atlanta VA Medical Center
-
Contact:
- Sierra Williams
- Telefoonnummer: 404-778-4729
- E-mail: sierra.williams@emory.edu
-
Hoofdonderzoeker:
- Mohammad Hajiha, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
- Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included
Exclusion Criteria:
- Dementia or cognitive impairment per provider clinical assessment
- Unable to give informed consent in the judgement of the patient's oncology provider
- Recurrent prostate cancer after primary treatment
- Less than 18 years of age at the time of informed consent
- Diagnosis of active second malignancy requiring treatment
- Individuals who are not able to clearly understand English since the outcome measures require understanding of English
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Group I (standard SCP, tailored SCP)
Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes. |
Ancillary studies Receive a low literacy educational supplement
Andere namen:
Undergo a structured interview Receive standard SCP
Andere namen:
Receive a tailored SCP
Andere namen:
|
|
Actieve vergelijker: Group II (standard SCP)
Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes. |
Ancillary studies Undergo a structured interview Receive standard SCP
Andere namen:
Receive a tailored SCP
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Comprehension of survivorship care recommendations and prostate specific antigen surveillance
Tijdsspanne: At baseline and up to 3 month phone call
|
Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard survivorship care plan (SCP) compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05. |
At baseline and up to 3 month phone call
|
|
Comprehension of treatment side effects and late effects
Tijdsspanne: At baseline and up to 3 month phone call
|
Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard SCP compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05. |
At baseline and up to 3 month phone call
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Access to survivorship care for late and long-term side effects
Tijdsspanne: At baseline and up to 3 month phone call
|
Will be assessed using the Patients Access Score (PAS). Descriptive statistics will be used to characterize patient access to survivorship care. The difference in mean PAS will be compared between the two arms using a 2 sample t-test. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Linear regression models will be used to identify predictors of access to survivorship care. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Decision regret
Tijdsspanne: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize decision regret. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Change in decisional conflict
Tijdsspanne: At baseline and up to 3 month phone call
|
The two-sample t-test will be used to evaluate the change in the average decisional conflict score between patients in the control arm (standard SCP) and patients in the intervention arm (standard SCP + tailoring + educational supplement). |
At baseline and up to 3 month phone call
|
|
Preparedness for survivorship
Tijdsspanne: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize preparedness for survivorship. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Patient self-efficacy
Tijdsspanne: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize patient self-efficacy. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Viraj Master, MD, PhD, FACS, Emory University Hospital/Winship Cancer Institute
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Genitale neoplasmata, mannelijk
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Genitale ziekten, man
- Prostaat Ziekten
- Mannelijke urogenitale ziekten
- Prostaatneoplasmata
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Onderzoekstechnieken
- Epidemiologische methoden
- Therapeutica
- Gegevensverzameling
- Evaluatiemechanismen voor gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Volksgezondheid
- Milieu en volksgezondheid
- Patiëntenzorg
- Gezondheidsdiensten
- Gezondheidszorgfaciliteiten personeel en diensten
- Child Health Services
- Community Health Services
- Preventieve gezondheidsdiensten
- Sociaaleconomische factoren
- Bevolkingskenmerken
- Methoden
- Interviews als onderwerp
- Palliatieve zorg
- Vroege interventie, educatief
- Educatieve status
Andere studie-ID-nummers
- STUDY00008365
- P30CA138292 (Subsidie/contract van de Amerikaanse NIH)
- STUDY00008365 (Andere identificatie: Emory University Hospital/Winship Cancer Institute)
- NCI-2024-08650 (Register-ID: CTRP (Clinical Trial Reporting Program))
- WINSHIP6368-24 (Andere identificatie: Emory University Hospital/Winship Cancer Institute)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .